| |
| Two title molecules, 6-bromo-2-(prop-2-ynylamino)-1H-benzo[de]isoquinoline -1,3(2H)-dione (4) and 6-bromo-2-(diprop-2-ynylamino)-1H-benzo[de]isoquinoline-1,3(2H)-dione (5), were synthesized and characterized by single-crystal X-ray diffraction, IR, 1H NMR, MS, fluorescence spectra, and powder X-ray diffraction (PXRD). The structure of crystal 4 (CCDC 981232) belongs to the triclinic system, space group P-1 with a = 7.5827(5), b = 7.8886(6), c = 10.5217(7) ?, α = 96.368(6), β = 90.223(5), γ = 92.353(6)o, V = 624.95(7) ?3, Dc = 1.749 g/cm3, μ = 4.52 mm-1, F(000) = 328, Rint = 0.0260, R (I > 2σ(I)) = 0.0622, wR (I > 2σ(I)) = 0.1454, R (all data) = 0.0683 and wR (all data) = 0.1484. In this crystal, a 2D layer supramolecular network structure was formed through hydrogen bonds of N(2)?H(2)oooO(1) and C(15)?H(15)oooO(1), and the Br atom was disordered over two positions with refined occupancies of 0.8589(3) and 0.1410(7). The calculated bond lengths and bond angles of compound 4 were consistent with the result of crystallography. Fluorescence properties of compounds 4 and 5 in different solvents were also studied. Moreover, the two synthesized compounds 4 and 5 were screened for their antimicrobial activities against seven bacteria and four fungi. Bioactive assay manifested that the two compounds exhibited moderate antibacterial and antifungal activities against the tested strains in comparison with the reference drugs norfloxacin, chloromycin and fluconazole. |
|
| Keywords:medicinal chemistry; synthesis; crystal structure; theoretical calculation; fluorescence spectra; bioactive assay |
|
